Suven Life Sciences Limited (BOM:530239)
India · Delayed Price · Currency is INR 358.20
+12.00 (3.47%)
At close: Jul 10, 2026
Suven Life Sciences Revenue
In the fiscal year ending March 31, 2026, Suven Life Sciences had annual revenue of 71.15M INR with 6.89% growth. Suven Life Sciences had revenue of 15.20M in the quarter ending March 31, 2026, with 3.62% growth.
Revenue
71.15M
Revenue Growth
+6.89%
P/S Ratio
1,327.74
Revenue / Employee
515.56K
Employees
138
Market Cap
94.46B
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 71.15M | 4.59M | 6.89% |
| Mar 31, 2025 | 66.56M | -50.37M | -43.08% |
| Mar 31, 2024 | 116.93M | -19.02M | -13.99% |
| Mar 31, 2023 | 135.95M | 16.44M | 13.76% |
| Mar 31, 2022 | 119.51M | -21.23M | -15.08% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| IOL Chemicals and Pharmaceuticals | 23.19B |
| Neuland Laboratories | 20.23B |
| Shilpa Medicare | 15.39B |
| Bajaj HealthCare | 6.11B |
| NGL Fine-Chem | 5.01B |
| Aarey Drugs & Pharmaceuticals | 4.72B |
| Sai Parenteral's | 3.81B |
| Anlon Healthcare | 1.72B |
Suven Life Sciences News
- 4 days ago - Suven Life Sciences allots 1.85 crore shares on preferential basis for Rs 248.84 crore - Business Upturn
- 4 days ago - Suven Life Sciences raises ₹248.84 crore through preferential allotment - Business Upturn
- 20 days ago - Suven Life Sciences to showcase CNS clinical candidates at BIO-2026 in San Diego - Business Upturn
- 25 days ago - Suven Life Sciences reports positive results from Ropanicant Phase-2b trial for depression - Business Upturn
- 26 days ago - Suven Life Sciences successfully completes Phase-1 Clinical Trial of SUVN-I6107 for CNS disorders - Business Upturn
- 4 weeks ago - Suven Life Sciences to present Phase-3 narcolepsy study at SLEEP-2026 - Business Upturn
- 5 weeks ago - Suven Life Sciences reports positive DSMB review in Alzheimer's study - Business Upturn
- 7 weeks ago - Suven Life Sciences shares rally over 17% today; Details here - Business Upturn